Circassia Pharmaceuticals PLC (GB:CIR)
LSE:CIR
UK Market

Circassia Pharmaceuticals Stock Analysis & Ratings

GB:CIR Stock Chart & Stats

Day’s Range36.55p - 36.8028p
52-Week Range0.26p - 33.40p
Previous Close36p
Volume50.99K
Average Volume (3M)792.09K
Market Cap153.89M
P/E Ratio45.6
Beta1.30
Next EarningsSep 29, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart Score8
EPS (TTM)0.01


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:CIR FAQ

What was Circassia Pharmaceuticals’s price range in the past 12 months?
Circassia Pharmaceuticals lowest stock price was 0.26p and its highest was 33.40p in the past 12 months.
    What is Circassia Pharmaceuticals’s market cap?
    Circassia Pharmaceuticals’s market cap is 153.89M.
      What is Circassia Pharmaceuticals’s price target?
      Currently, no data Available
      What do analysts say about Circassia Pharmaceuticals?
      Not enough analysts have published a price target to provide an average price target.
      When is Circassia Pharmaceuticals’s upcoming earnings report date?
      Circassia Pharmaceuticals’s upcoming earnings report date is Sep 29, 2022 which is in 132 days.
        How were Circassia Pharmaceuticals’s earnings last quarter?
        Circassia Pharmaceuticals released its earnings results on Mar 22, 2022. The company reported 1.1p earnings per share for the quarter, beating the consensus estimate of N/A by 1.1p.
          Is Circassia Pharmaceuticals overvalued?
          According to Wall Street analysts Circassia Pharmaceuticals’s price is currently Overvalued.
            Does Circassia Pharmaceuticals pay dividends?
            Circassia Pharmaceuticals does not currently pay dividends.
            What is Circassia Pharmaceuticals’s EPS estimate?
            Circassia Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Circassia Pharmaceuticals have?
            Circassia Pharmaceuticals has 419,320,000 shares outstanding.
              What happened to Circassia Pharmaceuticals’s price movement after its last earnings report?
              Circassia Pharmaceuticals reported an EPS of 1.1p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -6.985%.
                Which hedge fund is a major shareholder of Circassia Pharmaceuticals?
                Currently, no hedge funds are holding shares in GB:CIR

                ---

                Circassia Pharmaceuticals Stock Analysis

                Smart Score
                8
                Outperform
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10
                Price Target
                No data currently available

                Analyst Forecast

                N/A
                Currently Not Enough Data Available

                Blogger Sentiment

                N/A
                Currently Not Enough Data Available

                Hedge Fund Holdings

                N/A
                Currently Not Enough Data Available

                Insider Transactions

                ▲ Bought Shares
                Worth £59.5K over the Last 3 Months

                Retail Investors

                N/A
                Currently Not Enough Data Available

                News Sentiment

                Neutral
                Bullish 50% Bearish 50%

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                13.38%
                12-Months-Change

                Fundamentals

                Return on Equity
                3.46%
                Trailing 12-Months
                Asset Growth
                -16.20%
                Trailing 12-Months
                The Circassia Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Circassia Pharmaceuticals PLC

                Circassia Group PLC is a biotechnology company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of revenue from the US and also has a presence in EU, Asia Pacific and Rest of world.

                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Allied Minds
                4d Pharma
                ReNeuron Group
                Indivior

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis